Почетна › Многи мијелом › Merilend
Kliničke studije za Многи мијелом u državi Merilend
23 studija za Многи мијелом traži učesnike na lokacijama u državi Merilend.
Gradovi u državi Merilend
Zvanični tekst studije (na engleskom)
18F-Fluciclovine PET/CT in Multiple Myeloma
- National Institutes of Health Clinical Center, Bethesda
Тражи се учесникФаза 2
Узраст од 18 до 120 · Оба пола · Ажурирано 12. 11. 2026. · NCT06103838Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
- National Institutes of Health Clinical Center, Bethesda
Тражи се учесникОпсервациона студија
Узраст од 18 до 120 · Оба пола · Ажурирано 12. 11. 2026. · NCT02682667A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Johns Hopkins University School of Medicine JHUSOM, Baltimore
- Center for Cancer and Blood Disorders, Bethesda
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT05552222A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- University of Maryland School of Medicine, Baltimore
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07258511Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
- National Institutes of Health Clinical Center, Bethesda
Тражи се учесникФаза 1
Узраст од 18 до 120 · Оба пола · Ажурирано 2. 11. 2026. · NCT06904066A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- University of Maryland Greenbaum Comprehensive Cancer Center, Baltimore
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT07280013Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- National Institutes of Health Clinical Center, Bethesda
Тражи се учесникФаза 2
Узраст од 18 до 72 · Оба пола · Ажурирано 30. 10. 2026. · NCT03412877Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda
Тражи се учесникФаза 4
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT07609940Collection of Tissue Samples for Cancer Research
- Johns Hopkins University, Baltimore
- National Institutes of Health Clinical Center, Bethesda
Тражи се учесникОпсервациона студија
2 Months · Оба пола · Ажурирано 27. 10. 2026. · NCT00900198Tissue Collection for Studies of Lymph Cancer
- National Institutes of Health Clinical Center, Bethesda
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT01676805Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Johns Hopkins Asthma & Allergy Center, Baltimore
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT07648264A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- University of Maryland | Greenebaum Cancer Center, Baltimore
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06980480Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Тражи се учесникРана фаза 1
Узраст 18 и старији · Оба пола · Ажурирано 5. 10. 2026. · NCT06398457A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Johns Hopkins Hospital, Baltimore
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2026. · NCT07518186A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
- Maryland Oncology Hematology, Columbia
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 9. 2026. · NCT07637578A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Bethesda
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 25. 8. 2026. · NCT07227311Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Baltimore
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 14. 8. 2026. · NCT07764978Integrated Cancer Repository for Cancer Research
- Northwest Hospital, Randallstown
- William E. Kahlert Regional Cancer Center, Westminster
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст од 19 до 110 · Оба пола · Ажурирано 29. 6. 2026. · NCT02012699Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- The Center for Cancer and Blood Disorders (CCBD), Bethesda
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 24. 6. 2026. · NCT04068597Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Greater Baltimore Medical Center, Baltimore
Тражи се учесникФаза 3
Сви узрасти · Оба пола · Ажурирано 10. 6. 2026. · NCT05561387Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Maryland Oncology Hematology, Columbia
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 22. 4. 2026. · NCT05972135A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Sibley Memorial Hospital, Baltimore
- University of Maryland, Baltimore
- Johns Hopkins Main Center, Baltimore
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 24. 3. 2026. · NCT04988555A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
- Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 5. 9. 2025. · NCT05372354Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.